Delivery Order SPE2DR25D1002-SPE2DR26FGJ3B
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,542.07 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on September 10, 2025, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. HUMIRA is a leading biologic immunosuppressant medication used to treat various...
- The Defense Logistics Agency has awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40 mg/0.8 mL units. This competitively awarded, firm fixed price contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication for treating autoimmune conditions including rheumatoid arthritis,...
- The Defense Logistics Agency awarded a $36,425.77 delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40mg/4ml (2 units) under a firm fixed price contract. This delivery order, issued on October 27, 2025, with an ultimate completion date of November 24, 2025, represents a non-competitive, non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been selected to fulfill this medical supply...
- The Defense Logistics Agency awarded a $43,110.46 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, with final delivery required by July 15, 2025. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the delivery at its corporate office location. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA(CF) Pen 40 mg/0.4 mls on October 24, 2025, with an ultimate completion date of October 27, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a biologic medication used to treat autoimmune conditions. The contract is valued at $6,817.16 and is classified as a firm fixed-price delivery order with an ultimate completion date of October 23, 2025. The award uses no set-aside designation, indicating it was competitively awarded. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $2,265.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 28, 2025, with an ultimate completion date of August 29, 2025. This non-set-aside contract represents a pharmaceutical supply delivery under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery location is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mls, a biologic medication used primarily for autoimmune disease treatment. This competitive delivery order, valued at $2,910.65, was issued on October 28, 2025, with an ultimate completion date of October 29, 2025. The contract employs firm fixed-price pricing and carries no set-aside designation, indicating AmerisourceBergen competed openly against other qualified...
- The Defense Logistics Agency awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded contract employs firm fixed price pricing with no set-aside designation. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. HUMIRA is a biologic medication commonly used...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen 40 mg/0.4 mL, a biologic medication used primarily for autoimmune conditions. This firm fixed-price delivery order, valued at $7,754.51, was competitively awarded with no set-aside designation and carries an ultimate completion date of June 25, 2025. The order will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, the company's headquarters...
- SPE2DR25D1002Indefinite Delivery Contract
- SPE2DR25D1002-SPE2DR26FGJ3BDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,207.72 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on November 3, 2025, with an ultimate completion date of November 4, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen supplies a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare systems. HUMIRA is a widely-used biologic medication for treating autoimmune conditions including rheumatoid arthritis, and this delivery order represents a routine pharmaceutical procurement under the DLA's global pharmaceutical support vehicle, which enables AmerisourceBergen to fulfill medical supply needs across the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 11/3/25 |